1427370-43-1

Basic information

• Product Name: 4-(4-ethylbenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzenemethanol
• Synonyms: 4-(4-ethylbenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzenemethanol
• CAS NO: 1427370-43-1
• Molecular Weight: 748.959
• Mol File: 1427370-43-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(4-ethylbenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzenemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-ethylbenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzenemethanol(1427370-43-1)
• EPA Substance Registry System: 4-(4-ethylbenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzenemethanol(1427370-43-1)

Safety Data

• Hazardous Substances Data: 1427370-43-1(Hazardous Substances Data)

Upstream product

• 87808-49-9 2-bromo-4-methyl-benzoic acid methyl ester 
• 1427370-42-0 (2S,3S,4R,5R,6R)-2-[2-(allyloxymethyl)-5-(4-ethylbenzyl)phenyl]-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran 
• 1260424-47-2 2-bromo-4-(4-ethylbenzyl)benzenemethanol 
• 1427370-40-8 2-bromo-4-(4-ethylbenzoyl)benzoic acid methyl ester 
• 1427370-39-5 2-bromo-4-(4-ethylbenzoyl)benzoic acid methyl ester 
• 60728-41-8 1-methyl-2-aminoterephthalate 
• 264272-63-1 2-bromo-1,4-benzenedicarboxylic acid,1-methyl ester 

Downstream Products

• 1427370-45-3 (2R,3S,4S,4aR,10bS)-9-(4-ethylbenzyl)-3,4-dihydroxy-2-(hydroxymethyl)-3,4,4a,10b-tetrahydropyrano[3,2-c][2]benzopyran-6(2H)-one 
• 1427370-44-2 4-(4-ethylbenzyl)-2-[(2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl]benzoic acid 

Relevant articles and documents

Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof

The present invention relates to new pyrano[3,2-c]benzopyran-6(2H)-one derivatives that act as SGLT2 inhibitors, which makes them promising candidates for the treatment of diabetes and other diseases and conditions mediated by SGLT2. These new drugs also exhibit platelet aggregation inhibitory activity which makes them promising candidates in the treatment and/or prevention of prothrombotic conditions. The invention also relates to the use of such pyrano[3,2-c]benzopyran-6(2H)-one derivatives in the treatment or prevention of the diabetes and other disorders and conditions mediated by SGLT2, as a single active ingredient or in combination with another antidiabetic agent or a drug for the treatment of hypertension, chronic heart failure or atherosclerosis, and pharmaceutical compositions comprising said new pyrano[3,2-c]benzopyran-6(2H)-one derivatives.